The raised guidance and strong operating metrics (35% revenue growth, 20% EBITDA margin, record shipments) suggest accelerating commercial momentum. Traders should watch for continued RPO conversion and further reimbursement expansion as catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $16.60entry
- T+1 · 3mo ago −0.78%α −1.48% · $16.47
- T+5 · 3mo ago −8.61%α −8.17% · $15.17
- T+20 · 2mo ago −16.20%α −14.31% · $13.91
- T+60 · 12d ago −36.08%α −30.97% · $10.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay reported Q2 2026 revenue of $17.1M (+35% YoY), EPS of $0.07 (GAAP), and raised FY 2026 revenue guidance to $68-70M and Adjusted EBITDA guidance to $13-14M. The record system shipments (125 units, +42% YoY) and RPO growth to $80.4M (+30% YoY) signal strong demand momentum, while operating margin expanded to 14% from 5% YoY. The stock is likely to react positively given the beat on consensus estimates ($0.19 vs $0.07 EPS estimate, though GAAP EPS was $0.07) and raised guidance.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $17.1M, +35% YoY from $12.6M
- GAAP EPS $0.07 (basic and diluted), net income $2.7M
- Adjusted EBITDA $3.5M, +141% YoY, margin 20%
- Record 125 Deep TMS systems shipped, +42% YoY
- RPO $80.4M, +30% YoY
- Raised FY 2026 revenue guidance to $68-70M (from $66-68M)
- Raised FY 2026 Adjusted EBITDA guidance to $13-14M (from $12-14M)
- Operating cash flow $6.3M in Q2 2026
- Cash and equivalents $62.1M as of June 30, 2026
Financial Impact
Revenue beat consensus by $0.6M ($17.1M vs $16.5M est); GAAP EPS $0.07 vs $0.07 consensus (in-line); raised FY guidance implies ~30-34% revenue growth and ~90-100% EBITDA growth YoY
Risk Factors
- Guidance assumes continued reimbursement expansion and utilization growth, which may not materialize if payer coverage slows
- Competition from other TMS and neurostimulation modalities could pressure market share
- Dependence on FDA-cleared indications (MDD, OCD, smoking addiction) limits addressable market without new approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343549 |
Track record
24 reports on BWAY
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $10.11 −5.25% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $10.11 −8.84% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $10.11 −8.84% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $10.11 −9.81% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $10.11 −11.63% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $10.11 −15.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $10.11 −15.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $10.11 −15.18% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $10.11 −28.60% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers